Bloomberg -- Merck KGaA slumped the most in 14 years in Frankfurt trading after the European Union rejected its Erbitux drug for a form of lung cancer, denting growth prospects for the company’s top-selling oncology treatment.
Bloomberg -- Merck KGaA slumped the most in 14 years in Frankfurt trading after the European Union rejected its Erbitux drug for a form of lung cancer, denting growth prospects for the company’s top-selling oncology treatment.
